In March this year the Pharmaceutical Benefits Advisory Committee (PBAC), recommended a modified version of glatiramer acetate (Copaxone) for reimbursement on the Pharmaceutical Benefits Scheme. This medication for relapsing remitting MS became available on the PBS as of 1 August, 2015.
It is one of a number of modifying drugs which has been shown to reduce the frequency of relapses in people with Relapsing-Remitting Multiple Sclerosis (RRMS).
MS Australia welcomes the news that another affordable treatment option which has undergone rigorous clinical testing is available for people living with the condition in Australia.
Deidre Mackechnie, CEO at MS Australia said: We’re pleased that people living with relapsing-remitting MS across Australia are able to consider another affordable treatment option to help reduce the number of relapses they might experience. While this medication has been available for a while, it’s great that some people will benefit from the convenience of being able to administer it just three times a week rather than every day given the double strength dosage.
"It’s an exciting time for MS research with many discoveries being made in the last few years. While there is still no cure, these treatments can help people to live their lives to the fullest.”
Please visit MS Research Australia’s website for further information.